Proteome analysis of human substantia nigra in Parkinson's disease

被引：209
作者：
Basso, M
Giraudo, S
Corpillo, D
Bergamasco, B
Lopiano, L
Fasano, M
机构：
[1] Univ Insubria, Ctr Neurosci, Arsizio, VA, Italy
[2] Univ Insubria, Dept Struct & Funct Biol, Arsizio, VA, Italy
[3] Univ Turin, Dept Neurosci, Turin, Italy
[4] Bioind Pk Canavese, Colleretto Giacosa, Italy
[5] Salvatore Maugeri Fdn, Pavia, Italy
来源：
PROTEOMICS | 2004年 / 4卷 / 12期
关键词：
excitotoxicity; mitochondrial impairment; oxidative stress; Parkinson's disease; protein expression;
D O I：
10.1002/pmic.200400848
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Protein expression has been compared in human substantia nigra specimens from Parkinson's disease (PD) patients and from controls, and 44 proteins expressed in this midbrain region were identified by peptide mass fingerprinting. Among them, nine showed changes in their abundance. L and M neurofilament chains are less abundant in PD specimens, whereas peroxiredoxin II, mitochondrial complex III, ATP synthase D chain, complexin I, profilin, L-type calcium channel delta-subunit, and fatty-acid binding protein are significantly more present in PD samples than in controls. Besides the consolidated view of oxidative stress involvement in PD pathogenesis, suggested by overexpression of mitochondrial and reactive oxygen species (ROS)-scavenging proteins, these results indicate a possible potentiation mechanism of afferent signals to substantia nigra following degeneration of dopaminergic neurons.
引用
收藏
页码：3943 / 3952
页数：10
相关论文
共 50 条
[21]   Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation [J].
Kanda, S ;
Bishop, JF ;
Eglitis, MA ;
Yang, Y ;
Mouradian, MM .
NEUROSCIENCE, 2000, 97 (02) :279-284
[22]   Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders [J].
Krapfenbauer, K ;
Engidawork, E ;
Cairns, N ;
Fountoulakis, M ;
Lubec, G .
BRAIN RESEARCH, 2003, 967 (1-2) :152-160
[23]   Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease [J].
Krüger, R ;
Kuhn, W ;
Müller, T ;
Woitalla, D ;
Graeber, M ;
Kösel, S ;
Przuntek, H ;
Epplen, JT ;
Schöls, L ;
Riess, O .
NATURE GENETICS, 1998, 18 (02) :106-108
[24]   Parkinson's disease - First of two parts [J].
Lang, AE ;
Lozano, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (15) :1044-1053
[25]   The ubiquitin pathway in Parkinson's disease [J].
Leroy, E ;
Boyer, R ;
Auburger, G ;
Leube, B ;
Ulm, G ;
Mezey, E ;
Harta, G ;
Brownstein, MJ ;
Jonnalagada, S ;
Chernova, T ;
Dehejia, A ;
Lavedan, C ;
Gasser, T ;
Steinbach, PJ ;
Wilkinson, KD ;
Polymeropoulos, MH .
NATURE, 1998, 395 (6701) :451-452
[26]  
Lewy F.H., 1912, Handbuch der Neurologie, P920
[27]   Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation [J].
Lopiano, L ;
Fasano, M ;
Giraudo, S ;
Digilio, G ;
Koenig, SH ;
Torre, E ;
Bergamasco, B ;
Aime, S .
NEUROCHEMISTRY INTERNATIONAL, 2000, 37 (04) :331-336
[28]   Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease [J].
Lotharius, J ;
Brundin, P .
HUMAN MOLECULAR GENETICS, 2002, 11 (20) :2395-2407
[29]   Molecular basis of the neurodegenerative disorders [J].
Martin, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (25) :1970-1980
[30]   Sealed with a twist: complexin and the synaptic SNARE complex [J].
Marz, KE ;
Hanson, PI .
TRENDS IN NEUROSCIENCES, 2002, 25 (08) :381-383
12345